CliffBio
small molecule

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Loss of exclusivity—loss of exclusivity
CompanyKEY THERAPEUTICS LLC

Drug detail

Brand nameBUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Active ingredientACETAMINOPHEN; BUTALBITAL; CAFFEINE
Strength300MG;50MG;40MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2017
Marketing statusDISCN

More from KEY THERAPEUTICS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE patent cliff — loss of exclusivity — | CliffBio